Citi Says Buy CVS (CVS) Ahead of Q3 Results as Walgreen/Express Scripts Talks Ongoing

Citi's Deborah Weinswig is telling clients to purchase shares of CVS Caremark (NYSE: CVS) ahead of the company's third-quarter results on Thursday, November 3rd.

The analyst believes CVS's quarterly same-store sales will show strong growth as customers transfer prescriptions from Walgreen (NYSE: WAG) amid ongoing discussions between it and Express-Scripts (Nasdaq: ESRX).

Weinswig boosted her price target on shares of CVS from $44 to $45 and maintained a Buy rating.

With CVS shares up very modestly to $35.58 Monday morning, Citi's price target suggests potential upside of about 26 percent.

Track all the market-moving analyst action on shares of CVS Caremark with our Analyst Ratings page.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold
• Raymond James Starts Southern California Bancorp (BCAL) at Outperform